AFT Pharmaceuticals’ shares fall as drug fails FDA threshold

AFT Pharmaceuticals’ shares fall as drug fails FDA threshold
AFT Pharmaceuticals managing director Hartley Atkinson still believes Pascomer shows promise. (Image: AFT Pharmaceuticals)
Riley Kennedy
AFT Pharmaceuticals’ shares have fallen this morning after the company said a drug it is developing to treat facial angiofibromas (FA) had failed to reach the threshold for US Food and Drug Administration (FDA) registration.The company’s shares declined 3.3% to $3.80 in morning trading, after the pharmaceutical company released the findings of its study of its orphan drug Pascomer, which it said found “statistically significant” benefits. However, it did not reach the threshold on the IGA scale – a five-point...

More Markets

Spark sells remaining Connexa stake for $314m
Markets

Spark sells remaining Connexa stake for $314m

The sale will result in a $70m gain on telco's books.

Ben Moore 11:45am
Zespri on track for 'moderate increase' in volume next year
Primary Sector

Zespri on track for 'moderate increase' in volume next year

Zespri's producer vote to expand global supply passed this week.

Neal Barclay to exit Meridian as CEO
Markets

Neal Barclay to exit Meridian as CEO

Current CFO Mike Roan will take Barclay's spot atop Meridian.

Todd Corp: what went wrong?
Finance

Todd Corp: what went wrong?

A dividend freeze as the family empire rebuilds for the future.